Dr. Perales on the Future of CAR T-Cell Therapy in DLBCL and Follicular Lymphoma

Video

Miguel-Angel Perales, MD, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

Miguel-Angel Perales, MD, deputy chief, Adult Bone Marrow Transplant Service, director, Adult Bone Marrow Transplantation Fellowship Program, Memorial Sloan Kettering Cancer Center, discusses the future of CAR T-cell therapy in diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma.

There is potential to move CAR T cells earlier in treatment of patients with DLBCL and follicular lymphoma, says Perales. Studies have examined earlier CAR T-cell therapy in mantle cell lymphoma, while other studies looked at combining CAR T cells with checkpoint inhibitors. The results of those studies still need to be released, says Perales.

The results of CAR T-cell therapy in follicular lymphoma are promising, he adds. A study from the University of Pennsylvania looked at a small group of 14 patients and showed positive survival curves with this approach. Another study examined a different small group of patients with follicular lymphoma versus patients with transformed follicular lymphoma. Results from the study showed that patients with follicular lymphoma responded better to CAR T-cell therapy than those with transformed follicular lymphoma. These results were similar to that of the study conducted at the University of Pennsylvania, concludes Perales.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.